Cite
APA Citation
Hurvitz, S. A., Quek, R. G., Ettl, J., Rugo, H., Bhattacharyya, H., Hannah, A. L., & Litton, J. K. (n.d.). patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulation. Breast, 41, S27–S28. http://access.bl.uk/ark:/81055/vdc_100070083122.0x00002e